Globus Medical (GMED) Tops Q2 EPS by 7c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Globus Medical (GMED) PT Raised to $78 at RBC Capital
August 7, 2024 7:00 AM EDTRBC Capital analyst Shagun Singh raised the price target on Globus Medical (NYSE: GMED) to $78.00 (from $76.00) while maintaining a Outperform rating.
The analyst comments "GMED issued Q2 results, delivering an upside surprise of 2% and 11% in sales and EPS, respectively. This was the third consolidated... More
Globus Medical (GMED) PT Raised to $79 at Truist Securities
August 7, 2024 6:08 AM EDTTruist Securities analyst Richard Newitter raised the price target on Globus Medical (NYSE: GMED) to $79.00 (from $78.00) while maintaining a Hold rating.
The analyst comments "GMED delivered a good qtr, post-deal integration with dissynergies no worse than feared, and mgmt appears on... More
Globus Medical (GMED) PT Raised to $100 at Roth/MKM
August 7, 2024 5:17 AM EDTRoth/MKM analyst Jason Wittes raised the price target on Globus Medical (NYSE: GMED) to $100.00 (from $75.00) while maintaining a Buy rating.
The analyst comments "GMED reported 2Q24 revenues of $629.7 million compared to consensus of $615.3 million, and adjusted EPS of $0.75 compared to consensus of $0.68. Adjusted... More
